• X Chen, S Zhang, and C Bai.
• Institute of Respiratory Diseases, Zhongshan Hospital, Shanghai 200032.
• Zhonghua Jie He He Hu Xi Za Zhi. 1998 Apr 1; 21 (4): 233-5.

ObjectiveEpidermal growth factor (EGF) and its receptor play a critical role in the growth and regulation of many type of malignant cell. The high level of expression of the EGFR on normal cell lung cancer(NSCLC) and the important role of EGFR in signal transduction make it potentially an excellent target for antibody directed therapy. The purpose of this study was to evaluate the anti-tumor effects of anti-EGFR monoclonal antibody on lung carcinoma cells.MethodPreparation of hybrid cell producing anti-EGFR monoclonal antibody using EGF receptors partially purified from A431 cells as immunogen. The effect of anti-EGFR monoclonal antibody to human lung cells was investigated in vitro.ResultThe anti-EGFR monoclonal antibody was shown to inhibit the proliferation of human lung adenocarcinoma cells in vitro, but no growth-inhibitory effect was observed in the human small cell lung cancer cells. The concentration, 15 ug/ml, of anti-EGFR antibody could inhibit growth rate by 94% and 88% for human lung adenocarcinoma cell lines SPC A-1 and A549, respectively.ConclusionOur initial results indicate that the anti-EGF receptor monoclonal antibody may be potentially useful for the biotherapy of lung adenocarcinoma.

18 keywords...

hide…